- Home
- FIEE vs ATRA Comparison
FIEE vs ATRA Comparison
Compare FIEE & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FIEE | ATRA |
|---|---|---|
| Founded | 1977 | 2012 |
| Country | Hong Kong | United States |
| Employees | 43 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.6M | 38.9M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | FIEE | ATRA |
|---|---|---|
| Price | $5.19 | $9.63 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 6.6K | ★ 3.2M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.50 | $3.92 |
| 52 Week High | $7.95 | $19.15 |
Technical Indicators
Market Signals| Indicator | FIEE | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 40.08 | 55.95 |
| Support Level | $2.40 | $4.35 |
| Resistance Level | $7.28 | $12.91 |
| Average True Range (ATR) | 0.36 | 0.91 |
| MACD | -0.07 | -0.12 |
| Stochastic Oscillator | 37.40 | 32.03 |
Price Performance
Historical ComparisonAbout FIEE FiEE Inc
FiEE Inc, formerly Minim Inc is a digital service provider focused on integrating artificial intelligence and data analytics into content creation and brand management. The company offers a range of services designed to support creators, artists, and businesses in developing, managing, and optimizing their digital presence across various platforms, including customized graphic and posts, short videos, and editorial calendars aligned with brand goals.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).